中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

43 records (took 0.042 seconds)

    Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
    33.
    发明授权
    Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof 有权

    公开(公告)号：US10377824B2

    公开(公告)日：2019-08-13

    申请号：US16125028

    申请日：2018-09-07

    Applicant: BRISTOL-MYERS SQUIBB COMPANY

    Inventor： Nils Lonberg ,  Mohan Srinivasan

    IPC: A61K38/36 ,  A61K39/395 ,  C07K16/28 ,  A61K45/06 ,  A61K47/68 ,  C07K16/30 ,  A61K39/00

    Abstract: The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.

    Antibodies to TIGIT
    34.
    发明授权
    Antibodies to TIGIT 有权

    公开(公告)号：US10189902B2

    公开(公告)日：2019-01-29

    申请号：US14977789

    申请日：2015-12-22

    Applicant: Bristol-Myers Squibb Company

    Inventor： Mark F. Maurer ,  Tseng-hui Timothy Chen ,  Brigitte Devaux ,  Mohan Srinivasan ,  Susan H. Julien ,  Paul O. Sheppard ,  Daniel F. Ardourel ,  Indrani Chakraborty

    IPC: C07K16/00 ,  C12P21/08 ,  C07K16/28 ,  A61K39/00

    Abstract: The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.

    Antibodies to TIGIT
    39.
    发明授权
    Antibodies to TIGIT 有权

    公开(公告)号：US11008390B2

    公开(公告)日：2021-05-18

    申请号：US16228095

    申请日：2018-12-20

    Applicant: BRISTOL-MYERS SQUIBB COMPANY

    Inventor： Mark F. Maurer ,  Tseng-hui Timothy Chen ,  Brigitte Devaux ,  Mohan Srinivasan ,  Susan H. Julien ,  Paul O. Sheppard ,  Daniel F. Ardourel ,  Indrani Chakraborty

    IPC: C07K16/28 ,  A61P35/00 ,  A61K39/00

    Abstract: The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.

Patent Agency Ranking